SWY321 / CSPC Pharma - LARVOL DELTA

SWY2321, a novel topoisomerase I inhibitor linked bispecific ADC targeting EGFR/cMet, exhibits potent anti-tumor efficacy (AACR 2025) - "Especially in EGFR/cMet co-expressed NSCLC NCI-H1975 tumor model, SWY2321 showed excellent efficacy at 1.5 mg/kg single administration. In summary, the promising efficacy of SWY2321 supports that SWY2321 can be an effective treatment targeting multiple EGFR- or cMet- expressing solid tumors."

Clinical • Gastric Cancer • Lung Cancer • Non Small Cell Lung Cancer • Non-melanoma Skin Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • CTSB • EGFR